



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/30 (2006.01)

A61P 35/00 (2006.01) A61K 39/00 (2006.01)

C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2019/070886

(22) International Filing Date:

02 August 2019 (02.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/714,366 03 August 2018 (03.08.2018) US

(71) Applicants: AMGEN RESEARCH (MUNICH) GMBH

[DE/DE]; Staffelseestrasse 2, 81477 Munich (DE). AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: DAHLHOFF, Christoph; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). BLUEMEL, Claudia; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). BROZY, Johannes; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). RAUM, Tobias; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). NAHRWOLD, Elisabeth; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). ARVEDSON, Tara; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). CHEN, Irwin; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). ROSS, Sandra; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). BAILIS, Julie; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(74) Agent: WEINZIERL, Gerhard et al.; c/o Schiweck Weinzierl Koch, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODY CONSTRUCTS FOR CLDN18.2 AND CD3

(57) Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.